Tuberculosis is a prevalent and damaging infectious disease – approximately one third of the world’s population is infected. Of those people with latent infection, approximately 10% will develop clinical disease at some time during their lifetime.

Immunotherapy can be used to revert the disease-associated immune response of affected patients to that of healthy people. The most promising of such approaches has been to use heat-killed suspensions of the Mycobacterium vaccae combined with chemotherapy.

Invitation to contribute, on behalf of the Editorial Board

Now on Pubmed/Medline, this peer reviewed publication is at the forefront of clinical research - helping the healthcare community to meet the specific healthcare needs of women.

We are now actively soliciting contributions for the coming year in all aspects of therapeutics diagnostics, disease management, procedures and outcomes in women's healthcare today.

Specifically, we would like to encourage:

• Original Research Articles - new findings from
  studies and trials
• Reviews on current and emerging topics relating
  to the safe and effective management of
  therapy in women
• Drug Evaluations - overviews of individual
  therapies, placing the treatment in context with
  respect to issues such as efficacy, safety and
  comparative effectiveness

If you are interested in submitting an article to the
journal, contact me today to recieve one month's
free electronic access to the journal and to find out
more about our procedures and scheduling.

Joanne Walker
Clinical Submissions Manager